乌司他丁联合利奈唑胺对重症肺炎患者炎症反应及肺功能指标的影响

doi:10.3969/j.issn.1001-8131.2024.02.024

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (447 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of ulinastatin combined with Linezolid on inflammatory reaction and lung function indicators in patients with severe pneumonia. Methods 96 patients with severe pneumonia were selected and divided into two groups according to different treatment methods,with 48 cases in each group.The control group was treated with Linezolid,and the observation group was treated with ulinastatin combined with Linezolid for 4 weeks.Compare the clinical efficacy,inflammation levels,lung function,and adverse reactions between the two groups.The total effective rate of the observation group was 95.83%（46/48）,which was statistically significant（P<0.05）compared to 83.33%（40/48）of the control group;After treatment,in the observation group,the level of Calcitonin（PCT）was（340.57±57.34）ng/L,the level of C-reactive protein（CRP）was（10.02±3.21）mg/L,and tumor necrosis factor（TNF-α）The level was（10.87±8.21）pg/mL,lower than the control group's（510.36±62.37）ng/L,（25.69±5.31）mg/L,and（19.45±8.10）pg/mL;The index of forced expiratory volume（FEV1）in 1s was（50.02±0.25）%,the index of forced Vital capacity（FVC）was（67.38±8.97）%,and the index of maximum expiratory peak flow rate（PEF）was（2.05±0.35）L·s^-1,which was higher than that of the control group（45.31±1.15）%,（59.57±7.66）%,（1.54±0.27）L·s^-1,with statistical significance（P<0.05）;There was no statistically significant difference in adverse reactions between the two groups（P>0.05）. Conclusion The combination of Linezolid and ulinastatin can effectively alleviate the clinical symptoms,improve the lung function,reduce the inflammatory reaction in patients with severe pneumonia,and improve the clinical efficacy,which is safe and reliable.

Key words： Patients with severe pneumonia Ulinastatin Linezolid Inflammation Pulmonary functio

Received: 30 June 2023

PACS:

R563.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Ma Yingying

Cite this article:

Ma Yingying. Effects of Ulinastatin Combined with Linezolid on Inflammatory Reaction and Lung Function Indicators in Patients with Severe Pneumonia[J]. journal1, 2024, 44(2): 71-73.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.02.024 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I2/71

[1] 王娜,陈宇强,张琳,等.重症肺炎患者血清APC、IL-18的表达及其与临床预后的相关性[J].临床肺科杂志,2023,28(2):240-244248.
[2] Coste A,A Frérou,Raute A,et al.The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia:A Multicenter Cohort Study[J].Critical Care Medicine,2021,49(6):934-942.
[3] 宋园园,高辉,王本才,等.大剂量乌司他丁联合比阿培南辅助治疗对重症肺炎患者康复及血清炎性因子水平的影响[J].中国药物与临床,2021,21(22):3730-3732.
[4] 宋林燕,杨晓帆,黄正米,等.亚胺培南西司他丁联合利奈唑胺治疗老年重症肺炎的研究[J].西北药学杂志,2023,38(3):172-175.
[5] 葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:41-42.
[6] 蒋志敏,吴林军,雷建东,等.PCT、CysC联合检测在重症肺炎患者急性肾损伤预测中的临床价值[J].临床肺科杂志,2022,27(4):512-519.
[7] Tsai D,Secombe P,Chiong F,et al.Prediction accuracy of commonly used pneumonia severity scores in Aboriginal patients with severe community-acquired pneumonia-a retrospective study[J].Internal medicine journal,2023,53(1):51-60.
[8] 刘丽红,屈满英,刘莹,等.成人重症肺炎临床特征及病原学分析[J].中华急诊医学杂志,2022,31(11):1521-1525.
[9] 佘志远,江刚.乌司他丁治疗重症肺炎疗效的Meta分析[J].中国现代医学杂志,2021,31(13):94-100.
[10] 王娅宏,王海妮.亚胺培南西司他丁联合乌司他丁对重症肺炎并呼吸衰竭患者呼吸功能及血清炎性因子的影响评价[J].贵州医药,2023,47(3):428-430.
[11] 王昕,张英房,王宏艳.乌司他丁治疗脑出血并肺部感染患者的疗效及对炎性细胞因子的影响[J].河北医药,2021,43(3):428-430.
[12] 王斌霞,段露芬,陆件,等.利奈唑胺诱导血小板减少症的危险因素及其预警价值分析[J].药物不良反应杂志,2022,24(4):185-191.
[13] 李院玲,张艳.利奈唑胺治疗老年脑卒中合并MRSA肺部感染的疗效及成本-效果分析[J].医学临床研究,2022,39(12):1914-1916.
[14] 则学英,安春霞,刘磊.利奈唑胺联合美罗培南治疗重症肺炎疗效观察及对患者肺泡灌洗液中miR-127-5p、miR-3686表达的影响[J].中国药师,2021,24(5):884-888.
[15] 罗乐,黎松,张佩雯,等.盐酸氨溴索联合利奈唑胺治疗重症肺炎对血气指标及血清TNF-α、HMGB1的影响[J].西部医学,2021,33(7):1044-1047.